Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGACEP Phase II Multimodal Care of Inguinal Node Metastasis in Penile Squamous Cell Carcinoma
2024-512827-36-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide and cisplatin in penile squamous cell carcinoma (PSCC), sponsored by Unicancer. Primary endpoint: Survival without locoregional lymph node recurrence at 24 months. Planned start May 2024; status: authorised.
02
Drugs
paclitaxelifosfamidecisplatin
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2024-512827-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512827-36-00.